World's Best Scientists 2026 revealed!
Marcin Kowanetz

Marcin Kowanetz

D-Index & Metrics

Biology and Biochemistry

D-Index
57
Citations
33755
World Ranking
13503
National Ranking
5726

Overview

Marcin Kowanetz is affiliated with Genentech in the United States and has contributed extensively to the field of medicine, with a focus on oncology. Their research spans 65 publications in medicine, including 35 specifically dedicated to oncology and additional works in radiology, nuclear medicine, imaging, pulmonary and respiratory medicine, immunology, and molecular biology.

The scientist's main research topics include cancer immunotherapy and biomarkers, with 22 publications in this area; monoclonal and polyclonal antibodies research, with 18 publications; lung cancer treatments and mutations, with 16 publications; colorectal cancer treatments and studies, with 14 publications; radiopharmaceutical chemistry and applications, with 14 publications; immunotherapy and immune responses, with 10 publications; and CAR-T cell therapy research, with 8 publications.

Marcin Kowanetz has authored influential papers including:

  • Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy, 2020, Science Translational Medicine
  • Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity, 2020, Nature Cancer
  • Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade, 2021, Journal for ImmunoTherapy of Cancer
  • Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer, 2020, Clinical Lung Cancer
  • Abstract OT-03-02: Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors, 2021, Cancer Research

Frequent coauthors collaborating with Marcin Kowanetz include:

  • David Dornan, 12 publications
  • Michael N. Alonso, 12 publications
  • Shelley E. Ackerman, 11 publications
  • Alexander I. Spira, 10 publications
  • Karla A. Henning, 7 publications

Common publication venues for Marcin Kowanetz's work are:

  • Cancer Research (8 publications)
  • Regular and Young Investigator Award Abstracts (5 publications)
  • Journal of Clinical Oncology (3 publications)
  • Journal of Thoracic Oncology (2 publications)
  • Science Translational Medicine (1 publication)

Best Publications

  • Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

    Roy S. Herbst;Jean Charles Soria;Marcin Kowanetz;Gregg D. Fine

  • Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

    Achim Rittmeyer;Fabrice Barlesi;Daniel Waterkamp;Keunchil Park

  • Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

    Mark A. Socinski;Robert M. Jotte;Federico Cappuzzo;Francisco Orlandi

  • Atezolizumab Versus Docetaxel for Patients With Previously Treated Non-Small-Cell Lung Cancer (POPLAR): A Multicentre, Open-Label, Phase 2 Randomised Controlled Trial

    Louis Fehrenbacher;Alexander Spira;Marcus Ballinger;Marcin Kowanetz

  • Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

    Howard J West;Michael McCleod;Maen Hussein;Alessandro Morabito

  • Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

    David R. Gandara;Sarah M. Paul;Marcin Kowanetz;Erica Schleifman

  • Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.

    Martin Reck;Tony S K Mok;Makoto Nishio;Robert M Jotte

  • TGF-β and the Smad Signaling Pathway Support Transcriptomic Reprogramming during Epithelial-Mesenchymal Cell Transition

    Ulrich Valcourt;Marcin Kowanetz;Hideki Niimi;Carl-Henrik Heldin

  • Vascular Endothelial Growth Factor Signaling Pathways: Therapeutic Perspective

    M. Kowanetz;N. Ferrara

  • Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes

    Marcin Kowanetz;Xiumin Wu;John Lee;Martha Tan

  • G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models

    Farbod Shojaei;Xiumin Wu;Xueping Qu;Marcin Kowanetz

  • Id2 and Id3 Define the Potency of Cell Proliferation and Differentiation Responses to Transforming Growth Factor β and Bone Morphogenetic Protein

    Marcin Kowanetz;Ulrich Valcourt;Rosita Bergström;Carl-Henrik Heldin

  • Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).

    Solange Peters;Scott Gettinger;Melissa L. Johnson;Pasi A. Jänne

  • Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy.

    Maud Mayoux;Andreas Roller;Vesna Pulko;Stefano Sammicheli

  • Stable expression of angiopoietin-1 and other markers by cultured pericytes: phenotypic similarities to a subpopulation of cells in maturing vessels during later stages of angiogenesis in vivo.

    Christian Sundberg;Marcin Kowanetz;Lawrence F Brown;Michael Detmar

  • Elucidation of Smad Requirement in Transforming Growth Factor-β Type I Receptor-induced Responses

    Susumu Itoh;Midory Thorikay;Marcin Kowanetz;Aristidis Moustakas

  • Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer.

    Louis Fehrenbacher;Joachim von Pawel;Keunchil Park;Achim Rittmeyer

  • A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.

    Roy S. Herbst;Michael S. Gordon;Gregg Daniel Fine;Jeffrey Alan Sosman

  • IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.

    Robert M. Jotte;Federico Cappuzzo;Ihor Vynnychenko;Daniil Stroyakovskiy

  • Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM).

    Omid Hamid;Jeffrey Alan Sosman;Donald P. Lawrence;Ryan J. Sullivan

Frequent Co-Authors

Priti Hegde
Priti Hegde Genentech
Scott N. Gettinger
Scott N. Gettinger Yale University
Napoleone Ferrara
Napoleone Ferrara University of California, San Diego
David R. Gandara
David R. Gandara University of California, Davis
Fabrice Barlesi
Fabrice Barlesi Institut Gustave Roussy
Louis Fehrenbacher
Louis Fehrenbacher Kaiser Permanente
Naiyer A. Rizvi
Naiyer A. Rizvi Columbia University Medical Center
Mark A. Socinski
Mark A. Socinski University of North Carolina at Chapel Hill
David R. Spigel
David R. Spigel Sarah Cannon Research Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online education can open the door to a variety of specialized careers connected to biology and biochemistry. For those interested in human health and diet, online nutrition degrees provide a flexible path to enter fields like dietetics, wellness coaching, or public health.

If your focus is healthcare leadership, pursuing top cahme-accredited mha programs gives you advanced skills to manage hospitals or health organizations. These programs are highly respected in the healthcare industry and can be completed online to fit your schedule.

For nursing professionals, a dnp program no clinical is an excellent option to advance your expertise without the need for on-site clinical work. This can help you transition to policy, education, or executive roles in healthcare.

Additionally, if you want to research and shape healthcare systems at the highest level, a phd in healthcare management prepares you for academic, consulting, or high-level administrative positions.

Best Scientists Citing Marcin Kowanetz

Trending Scientists